{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:29:55Z","timestamp":1784917795839,"version":"3.55.0"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To investigate the safety and tolerability of evexomostat (SDX-7320) in patients with late-stage cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This phase 1 dose-escalation safety study used an accelerated titration followed by a 3 + 3 design on 7- or 14-day administration, with dose expansion at the recommended phase 2 dose in 32 patients with late-stage, solid tumors. Measurements included standard assessments of safety, tolerability, target engagement in whole blood, plasma levels of protein biomarkers, and drug exposure. Tumor response was measured using RECIST v.1.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirty-two patients were dosed with evexomostat (SDX-7320), starting at 1.7 mg\/m2 once per week and escalated to 65 mg\/m2 (once every 2 weeks, 28 days\/cycle). Dose escalation and expansion confirmed the maximum tolerated dose at 49 mg\/m2 once every 2 weeks with reversible thrombocytopenia as the dose-limiting toxicity. Most treatment-emergent adverse events were of grade 1 or 2 in severity and nonserious, with no grade 5 adverse events. Eighty percent of patients (n = 20\/25 evaluable) had stable disease, and the average treatment duration was 87 days (3.1 cycles). Key angiogenic biomarkers VEGF-C and bFGF (FGF2) improved in response to evexomostat. Patients with baseline insulin resistance (i.e., fasting insulin &amp;gt;20 \u00b5U\/mL; n = 11) exhibited significant decreased fasting insulin after treatment. Decreases in leptin were observed in 27\/31 patients (87%), whereas adiponectin increased in 28\/31 patients (90%). Plasma lipid profiles showed increased high-density lipoprotein (HDL) and decreased low-density lipoprotein (LDL) cholesterol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Evexomostat (SDX-7320) was well-tolerated with prolonged stable disease and metastatic control in an open-label, phase I safety study. Improvements were observed in angiogenic and metabolic biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Obesity and insulin resistance are known to promote tumor growth and accelerate the mortality of patients with cancer. Evexomostat is a novel antiangiogenic and antimetastatic drug candidate which also has insulin-sensitizing and antiobesity properties that is being developed for use in combination with standard-of-care therapies for obese patients with cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0627","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:18:29Z","timestamp":1748585909000},"page":"1008-1017","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8448-4854","authenticated-orcid":false,"given":"Monica M.","family":"Mita","sequence":"first","affiliation":[{"name":"1Hoag, Newport Beach, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3260-4793","authenticated-orcid":false,"given":"Alain C.","family":"Mita","sequence":"additional","affiliation":[{"name":"1Hoag, Newport Beach, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0081-4764","authenticated-orcid":false,"given":"Bradley J.","family":"Carver","sequence":"additional","affiliation":[{"name":"2SynDevRx Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1115-1519","authenticated-orcid":false,"given":"James M.","family":"Shanahan","sequence":"additional","affiliation":[{"name":"2SynDevRx Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8762-6650","authenticated-orcid":false,"given":"Benjamin A.","family":"Mayes","sequence":"additional","affiliation":[{"name":"2SynDevRx Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8476-1679","authenticated-orcid":false,"given":"Pierre J.","family":"Dufour","sequence":"additional","affiliation":[{"name":"2SynDevRx Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1486-7022","authenticated-orcid":false,"given":"David","family":"Browning","sequence":"additional","affiliation":[{"name":"2SynDevRx Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3901-5831","authenticated-orcid":false,"given":"Alfred","family":"Anderson-Villaluz","sequence":"additional","affiliation":[{"name":"3Nuvation Bio, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6006-8700","authenticated-orcid":false,"given":"John S.","family":"Petersen","sequence":"additional","affiliation":[{"name":"4Glyscend Therapeutics, Lowell, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5423-3174","authenticated-orcid":false,"given":"David J.","family":"Turnquist","sequence":"additional","affiliation":[{"name":"5Hemavant Sciences, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9448-3792","authenticated-orcid":false,"given":"Peter","family":"Cornelius","sequence":"additional","affiliation":[{"name":"2SynDevRx Inc., Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"2025062304503177100_bib1","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1158\/2767-9764.CRC-23-0048","article-title":"A first-in-human, dose-escalation study of the methionine aminopeptidase 2 inhibitor M8891 in patients with advanced solid tumors","volume":"3","author":"Carducci","year":"2023","journal-title":"Cancer Res Commun"},{"key":"2025062304503177100_bib2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/348555a0","article-title":"Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth","volume":"348","author":"Ingber","year":"1990","journal-title":"Nature"},{"key":"2025062304503177100_bib3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1517\/13543784.9.6.1383","article-title":"TNP-470: an angiogenesis inhibitor in clinical development for cancer","volume":"9","author":"Kruger","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"2025062304503177100_bib4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/dom.12457","article-title":"Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial","volume":"17","author":"Kim","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2025062304503177100_bib5","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/dom.14009","article-title":"The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: a randomized, placebo-controlled trial","volume":"22","author":"Wentworth","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2025062304503177100_bib6","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.1073\/pnas.97.12.6427","article-title":"Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1\/CIP1","volume":"97","author":"Zhang","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025062304503177100_bib7","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.chembiol.2006.07.010","article-title":"A chemical and genetic approach to the mode of action of fumagillin","volume":"13","author":"Zhang","year":"2006","journal-title":"Chem Biol"},{"key":"2025062304503177100_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3892\/or.2021.8242","article-title":"Methionine aminopeptidase-2 is a pivotal regulator of vasculogenic mimicry","volume":"47","author":"Shimizu","year":"2022","journal-title":"Oncol Rep"},{"key":"2025062304503177100_bib9","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/01.RES.0000132745.76882.70","article-title":"Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice","volume":"94","author":"Br\u00e5kenhielm","year":"2004","journal-title":"Circ Res"},{"key":"2025062304503177100_bib10","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1007\/s00125-018-4677-0","article-title":"Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial","volume":"61","author":"Proietto","year":"2018","journal-title":"Diabetologia"},{"key":"2025062304503177100_bib11","doi-asserted-by":"crossref","first-page":"10730","DOI":"10.1073\/pnas.162349799","article-title":"Adipose tissue mass can be regulated through the vasculature","volume":"99","author":"Rupnick","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025062304503177100_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1165\/rcmb.2006-0352OC","article-title":"Methionine aminopeptidase-2 as a selective target of myofibroblasts in pulmonary fibrosis","volume":"37","author":"Kass","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2025062304503177100_bib13","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/j.1523-1755.2004.00935.x","article-title":"TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model","volume":"66","author":"Yoshio","year":"2004","journal-title":"Kidney Int"},{"key":"2025062304503177100_bib14","first-page":"955","article-title":"Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458","volume":"28","author":"Hannig","year":"2006","journal-title":"Int J Oncol"},{"key":"2025062304503177100_bib15","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1073\/pnas.94.12.6099","article-title":"The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2","volume":"94","author":"Sin","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025062304503177100_bib16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1074-5521(99)80129-X","article-title":"Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells","volume":"6","author":"Turk","year":"1999","journal-title":"Chem Biol"},{"key":"2025062304503177100_bib17","first-page":"1989","article-title":"A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer","volume":"5","author":"Bhargava","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2025062304503177100_bib18","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1200\/JCO.2002.04.006","article-title":"Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer","volume":"20","author":"Herbst","year":"2002","journal-title":"J Clin Oncol"},{"key":"2025062304503177100_bib19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1158\/1535-7163.MCT-23-0574","article-title":"Pharmacological characterization of SDX-7320\/evexomostat: a novel methionine aminopeptidase type 2 inhibitor with anti-tumor and anti-metastatic activity","volume":"23","author":"Cornelius","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"2025062304503177100_bib20","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMoa021423","article-title":"Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults","volume":"348","author":"Calle","year":"2003","journal-title":"N Engl J Med"},{"key":"2025062304503177100_bib21","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3390\/biom13071084","article-title":"Leptin: a heavyweight player in obesity-related cancers","volume":"13","author":"Caruso","year":"2023","journal-title":"Biomolecules"},{"key":"2025062304503177100_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41568-020-0295-5","article-title":"Hyperinsulinaemia in cancer","volume":"20","author":"Gallagher","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"2025062304503177100_bib23","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1158\/1940-6207.CAPR-16-0322","article-title":"Signals from the adipose microenvironment and the obesity-cancer link-A systematic review","volume":"10","author":"Himbert","year":"2017","journal-title":"Cancer Prev Res (Phila)"},{"key":"2025062304503177100_bib24","doi-asserted-by":"crossref","first-page":"799","DOI":"10.4093\/dmj.2021.0077","article-title":"Obesity, diabetes, and increased cancer progression","volume":"45","author":"Kim","year":"2021","journal-title":"Diabetes Metab J"},{"key":"2025062304503177100_bib25","doi-asserted-by":"crossref","first-page":"10768","DOI":"10.1073\/pnas.0404105101","article-title":"A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis","volume":"101","author":"Bernier","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025062304503177100_bib26","first-page":"1501","article-title":"A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix","volume":"3","author":"Kudelka","year":"1997","journal-title":"Clin Cancer Res"},{"key":"2025062304503177100_bib27","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s00280-004-0816-z","article-title":"Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors","volume":"54","author":"Tran","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025062304503177100_bib28","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.3390\/ijms21145148","article-title":"The role of methionine aminopeptidase 2 in lymphangiogenesis","volume":"21","author":"Esa","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025062304503177100_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00595-003-2645-9","article-title":"Angiogenesis inhibitor TNP-470 can suppress hepatocellular carcinoma growth without retarding liver regeneration after partial hepatectomy","volume":"34","author":"Kinoshita","year":"2004","journal-title":"Surg Today"},{"key":"2025062304503177100_bib30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2174\/092986706776361085","article-title":"Antiangiogenesis drug design: multiple pathways targeting tumor vasculature","volume":"13","author":"Zhong","year":"2006","journal-title":"Curr Med Chem"},{"key":"2025062304503177100_bib31","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/oby.20356","article-title":"Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women","volume":"21","author":"Hughes","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"2025062304503177100_bib32","doi-asserted-by":"crossref","first-page":"E514","DOI":"10.1152\/ajpendo.00451.2019","article-title":"MetAP2 inhibitor treatment of high-fat and -fructose-fed dogs: impact on the response to oral glucose ingestion and a hyperinsulinemic hyperglycemic clamp","volume":"318","author":"Moore","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2025062304503177100_bib33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-5-32","article-title":"Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins","volume":"5","author":"Deprimo","year":"2007","journal-title":"J Transl Med"},{"key":"2025062304503177100_bib34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00280-013-2333-4","article-title":"Circulating proteins as potential biomarkers of sunitinib and interferon-\u03b1 efficacy in treatment-na\u00efve patients with metastatic renal cell carcinoma","volume":"73","author":"Harmon","year":"2014","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0627\/3611934\/crc-24-0627.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/6\/1008\/3623545\/crc-24-0627.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/6\/1008\/3623545\/crc-24-0627.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T04:50:42Z","timestamp":1750654242000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/6\/1008\/763101\/A-Phase-1-Safety-Study-of-Evexomostat-SDX-7320-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0627","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29381374","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381341","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381362","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381350","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381371","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381356","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381344","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381377","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381365","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381332","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381353","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381338","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381359","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381347","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381368","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29381335","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7888810","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]}}}